Dr. Pedro Barata, MD, MSc, of University Hospitals Seidman Cancer Center, discusses his research letter “Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer,” which examines patterns of HRR mutation genetic testing and the characteristics associated with testing among US patients with metastatic castration-resistant prostate cancer.
Enhancing Genetic Testing Rates in Metastatic Prostate Cancer: Trends, Challenges, and Opportunities
By Pedro Barata, MD - Last Updated: June 13, 2024Related Posts
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.
Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.
New research sheds light on the real-world outcomes of Lu-PSMA-617 in a racially diverse patient population.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.